The ErbB family is well known for its significance in oncogenesis. As bad prognostic
markers, overexpressed or mutated ErbB1 and ErbB2 have an important role in the …

Immunotherapy, based on mAbs specifically directed against cancer cells, is considered a
precious strategy in the fight against cancer because of its selectivity and lack of multidrug …

In the last 3-5 years strong evidence has been gathered demonstrating ErbB3 as a key node
for the progression of several cancer types. From the mechanistic standpoint the intracellular …

Over the past 3 decades, monoclonal antibodies and their related derivatives, including
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …

Antibodies targeting the extracellular domains of ErbB receptors have been extensively
studied for cancer drug development. This work has led to clinical approval of monoclonal …

ErbB1 and ErbB2 constitute validated target antigens for tumor therapy—as documented by
the approval of antibodies and tyrosine kinase inhibitors (TKIs) against both antigens …

ErbB3 is an important regulator of tumorigenesis and is implicated in development of
resistance to several currently used oncology drugs. We have identified ErbB3 inhibitors …

ErbB2 is a prognostic factor and target of therapy for many carcinomas. In contrast with the
other ErbB receptors, ErbB2 lacks a soluble direct ligand, but it is the preferred co-receptor …

Next-generation antibody (NGA) therapeutics with antibody architecture modifications
represent a key area of monoclonal antibody (mAb) research and development (R&D) …

Cancer progression depends on stepwise accumulation of oncogenic mutations and a
select group of growth factors essential for tumor growth, metastasis and angiogenesis …